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Abstract
Background: Tenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October
2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired
renal function.
Methods: We included all participants of the Swiss HIV Cohort Study on TDF-containing antiretroviral therapy with
follow-up visits after January 2016. We determined the proportion of switches from TDF to TAF overall, and among
patients with risk factors for TDF toxicity, including osteoporosis, impaired renal function or marked proteinuria. We
used multivariable logistic regression to explore predictors of switching from TDF to TAF.
Results: We included 5′012 patients, of whom 652 (13.0%) had risk factors for TDF toxicity. A switch from TDF to
TAF was undertaken in 2′796 (55.8%) individuals overall, and in 465 (71.3%) with risk factors. Predictors of switching
to TAF were male sex (adjusted odds ratio 1.27, 95% confidence interval 1.07–1.50), age > 50 years (1.43, 1.23–1.66)
and the presence of risk factors for TDF toxicity (2.21, 1.77–2.75). In contrast, patients with a non-nucleoside reverse
transcriptase inhibitor (NNRTI)-based single-pill regimen (0.11, 0.09–0.13), those treated in non-tertiary care centers
(0.56, 0.46–0.70), as well as those with CD4 cell counts below 500/μL (0.77, 0.66–0.90) and with chronic hepatitis C
infection (0.66, 0.54–0.80) were most likely to stay on TDF.
Conclusions: Over 50% of patients on TDF-containing therapy, including the majority of patients at risk for TDF
toxicity, were switched to TAF within two years of its introduction in Switzerland. Individuals on NNRTI-based
single-pill regimens were most likely to remain on TDF.
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Background
As AIDS-related mortality is decreasing worldwide, im-
proving the quality of life and preventing long-term side
effects of antiretroviral agents have become priorities in
the management of HIV infection. When treated with
antiretroviral therapy (ART), the average life expectancy
of HIV-infected individuals is similar to that of unin-
fected individuals [1, 2]. However, life-long ART exposes
persons living with HIV to treatment-associated toxicity
and potential drug-drug interactions (DDI) with other
medications, especially in an ageing population experien-
cing an increasing number of non-communicable co-
morbidities [3]. Therefore, the modification of ART to
regimens with minimal long-term toxicity and DDI is
generally encouraged.
Tenofovir disoproxil fumarate (TDF) is a highly potent
drug included in many first-line ART regimens recom-
mended in the past decade [4]. However, its use is asso-
ciated with bone mineral disorders and proximal renal
tubulopathy, which can lead to impaired renal function
[5–8]. Tenofovir alafenamide (TAF), a newer tenofovir
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prodrug, reaches high intracellular levels while exposing
patients to low plasma levels, an important driver of
tenofovir-related toxicity. TAF has the same antiviral ac-
tivity but a better renal and bone safety profile than
TDF: In registration trials, patients who switched from
TDF to TAF experienced an increase in bone mineral
density and a decrease in proteinuria and renal tubular
markers [9, 10]. Despite the lack of long-term safety and
efficacy data on the use of TAF outside of randomized
controlled trials, the International Antiviral Society–
USA (IAS-USA) advises against the use of TDF in pa-
tients at risk of kidney or bone disease [11]. In addition,
the European AIDS Clinical Society (EACS) defines the
following risk groups for which TAF should be preferred
to TDF in order to prevent long-term toxicity: (a) estab-
lished or high risk of chronic kidney disease; (b) con-
comitant use of nephrotoxic drugs, and (c) osteoporosis/
osteopenia, related risk factors or a history of fragility
fractures [12].
In Switzerland, TAF became available in combination
with emtricitabine/elvitegravir/cobicistat (F/TAF/EVG/c,
Genvoya®) in October 2016, with emtricitabine alone (F/
TAF, Descovy®) in May 2017, and with emtricitabine/ril-
pivirine (F/TAF/RPV, Odefsey®) in July 2018. These
drugs were introduced at a slightly lower price than their
TDF-containing counterparts, and no generic version of
TDF-containing compounds other than TDF as a single
substance are available to date in Switzerland. We used
data from the nationwide Swiss HIV Cohort Study
(SHCS) to determine the proportion of patients with
and without risk factors for TDF-related toxicity who
had been switched from TDF to TAF and explored indi-
vidual predictors for being switched.
Methods
Swiss HIV cohort study
The SHCS (www.shcs.ch) is a prospective cohort that
enrolls close to 80% of all HIV-infected adults living in
Switzerland [13]. Demographic, HIV-specific (e.g. date of
diagnosis, most probable mode of transmission) and la-
boratory data (e.g. plasma viral load, CD4 cell counts,
and lipid levels) are recorded at enrollment, and every 6
months thereafter. Clinical events (e.g. myocardial in-
farction, fragility fractures) are regularly reported using
dedicated forms, and a detailed history of ART and co-
medications is available for all participants. Local ethical
committees of all cohort centers approved this cohort
study and all patients provided written informed consent.
Study population, definitions and outcomes
We included all HIV-infected adults with one or more
clinical follow-up visits after January 1st 2016 and who
were on a TDF-containing regimen for more than 30
days. Patients were classified as having switched if TAF
was introduced within 90 days after stopping TDF, and if
TAF was continued for at least 14 days. To restrict our
analysis to direct switches from TDF to TAF, we ex-
cluded patients who were prescribed abacavir during the
time between the use of TDF and TAF. The decision to
switch or not was at the discretion of the treating phys-
ician, and no additional guidance was given. Database
closure was on the 1st of August 2018.
Our primary aim was to describe the proportion of pa-
tients having switched from TDF to TAF and to identify re-
lated predictors. Additionally, the same outcomes were
explored in patients “at risk of TDF toxicity”, defined as the
presence of at least one of the following risk factors: [1]
estimated glomerular filtration rate (eGFR) < 60mL/min,
[2] marked proteinuria (protein-to-creatinine ratio ≥
50 mg/mmol [≥500 mg/g]) or [3] osteoporosis (T-
score ≤ − 2.5 in any bone mineral density measure-
ment and/or occurrence of fragility fractures). Our
secondary aims were to explore the reasons for dis-
continuing TDF, as reported by treating physicians,
using pre-defined stopping reasons which are system-
atically recorded through an online tool. Finally, we
determined whether TAF was used together with
drugs that are categorized as “do not co-administer”
for TAF but not TDF according to the Liverpool
Drug Interaction Group Database [14], in order to
evaluate potential problematic DDI with TAF.
Arterial hypertension was defined as at least two mea-
surements > 140mmHg systolic or > 90mmHg diastolic
and/or currently being on antihypertensive treatment, dia-
betes mellitus as HbA1c ≥6.5% and/or currently being on
antidiabetic treatment and dyslipidemia as total-cholesterol
to HDL ratio > 5 and/or currently being on lipid lowering
treatment. Chronic hepatitis B virus (HBV) infection was
defined by the presence of a positive hepatitis B surface
antigen, and hepatitis C infection (HCV) as a detectable
HCV viral load at any time-point, irrespective of HCV
treatment. A history of cardiovascular disease included the
previous occurrence of any of the following: myocardial in-
farction, ischemic stroke, arterial interventions including
coronary angioplasty/stenting, coronary artery by-pass
grafting and venous thromboembolism.
Statistical analyses
We compared baseline demographic and clinical charac-
teristics, comorbidities and laboratory values between
patients “at risk of TDF toxicity” and those without risk
factors using Chi-square, Wilcoxon rank sum and t-
tests, where appropriate. Baseline was defined as [1]
switching date for patients on TAF, [2] October 1st 2016
for patients remaining on TDF, or [3] registration date
for patients remaining on TDF who joined the SHCS
after October 1st 2016. Multivariable logistic regression
was used to explore risk factors of switching to TAF,
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and included the following explanatory variables: sex,
age (< 50 or ≥ 50 years), region of origin, education
status, CD4 cell count (< 500 or ≥ 500/μL), follow-up
in a tertiary versus non-tertiary center (including pri-
vate physicians), comorbidities (chronic HBV or HCV
infections, history of cardiovascular disease, diabetes,
arterial hypertension and dyslipidemia), the presence
of at least one risk factor for TDF associated toxicity,
and use of boosted protease inhibitors (PI) or non-
nucleoside reverse transcriptase inhibitor (NNRTI)-
based single-pill regimens. Osteoporosis was excluded
from the multivariable analyses because bone mineral
density measurements were only available in one third
of patients. However, we repeated the main analyses
in patients with at least one risk factor for TDF tox-
icity, including osteoporosis and eGFR. Odds ratios
from multivariable analyses are presented in Forest
plots, stratified by the presence or absence of any risk
factors for TDF toxicity. All statistical analyses were
performed using Stata 15.1 (Stata Corp, College Sta-
tion, TX, USA).
Results
Study population
Of 10′246 HIV-infected individuals in active follow-up
after January 1st 2016, 8′245 (80.5%) ever received TDF
for more than 30 days. After excluding patients who
switched to abacavir or initiated TAF more than 90 days
after stopping TDF (n = 3′233), 5′012 patients remained
in our study population. Overall, 3′645 (72.7%) partici-
pants were male, 789 (15.7%) were of African origin, and
the median age was 49 years (interquartile range [IQR]
41–56). Measurements of creatinine and proteinuria at
baseline were available for 4′813 (96.0%) and 3′102 (61.9%)
patients respectively, and a bone densitometry measure-
ment was available in 1′624 (32.4%) individuals. In total,
652 patients (13.0%) had one or more risk factors for
TDF-associated toxicity: 243 had an eGFR < 60 mL/min
(4.8%), 154 (3.1%) had marked proteinuria, and osteo-
porosis was diagnosed in 325 (6.5%) patients. Table 1
summarizes the main demographic and clinical charac-
teristics of the study population, stratified by the pres-
ence of at least one risk factor for developing TDF-
related toxicity. Patients with risk factors were older,
less likely to be of African origin, but more likely to be
persons who inject drugs (PWID) and to have arterial
hypertension, dyslipidemia, diabetes or a history of car-
diovascular disease.
Rates and predictors of switching from TDF to TAF
Nearly two years after the introduction of TAF in
Switzerland, 2′796 (55.8%) individuals had TDF replaced
by TAF, with large differences across cohort centers,
ranging from 32.6 to 65.3% (p < 0.001). Overall, most
individuals received F/TAF and a third drug (n = 1′635,
58.5%), followed by F/TAF/EVG/c (n = 1′116, 39.9%)
and F/TAF/RPV (n = 45, 1.6%). In those who received F/
TAF, the most common third drug was dolutegravir
(661, 40.4%), followed by boosted darunavir (277,
16.9%), nevirapine (243, 14.9%) and raltegravir (130, 8%).
In 1475 (52.8%) instances, the switch from TDF to TAF
was the only modification in the ART regimen with all
other components remaining unchanged.
Of the 652 patients with at least one risk factor for
TDF-associated toxicity, 465 (71.3%) were switched to
TAF. Patients switched at a median of 9.7 months (IQR
7.1–12.2 months) after the introduction of TAF into the
Swiss market, without a significant difference between
those with or without TDF-toxicity risk factors (9.5 ver-
sus. 9.7 months, p = 0.15). Thirty-four patients had ac-
cess to TAF prior to its official licensing, either through
an early access program or within a study protocol, and
remained in our study population.
In multivariable analyses, patients were more likely to
switch to TAF if they were male, older than 50 years,
had at least one risk factor for TDF toxicity, or arterial
hypertension. In contrast, patients with CD4 cell counts
below 500/μL, those followed in non-tertiary centers,
and HCV-coinfected individuals were more likely to re-
main on TDF. An important predictor for staying on
TDF was the use of NNRTI-based single-pill regimens
(Table 2), with comparable estimates for efavirenz and
rilpivirine based single-tablet regimens. Compared to the
population without risk factors, the proportion of indi-
viduals who switched to TAF was higher in the presence
of an eGFR < 60mL/min (77.4%), osteoporosis (71.4%), or
marked proteinuria (64.9%, Fig. 1). In patients with an
eGFR < 60mL/min who remained on TDF, median eGFR
at baseline was 56.5mL/min (IQR 52.6–58.0mL/min) and
none had an eGFR ≤30mL/min.
In analyses restricted to patients with TDF-related
risk factors, the associations between switching to
TAF and renal impairment, the use of NNRTI-based
single-pill regimens and co-infection with HCV
remained statistically significant. In contrast, higher
age, male sex or the presence of arterial hypertension
were not associated with switching to TAF among
persons with TDF-related risk factors. (Fig. 2a and b).
The most common ART regimens in patients staying
on TDF despite TDF-related risk factors were fixed-
dose combinations of F/TDF/RPV (31.6%) and F/
TDF/efavirenz (25.1%).
Reasons for switching from TDF to TAF and presence of
drug-drug interactions
The main reasons for replacing TDF by TAF, as reported
by SHCS physicians, were “prevention of expected side-
effects” (24.9%), followed by “simplification of current
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treatment” (9.2%), and “presence of established kidney
toxicity” (8.2%) (Table 3). Less specific reasons such
as patient’s wish and physician’s decision were given
in 1′372 cases (49.1%). The use of drugs which are
contraindicated with TAF was rare in our cohort:
Three individuals switched to TAF (all once-daily)
while taking rifabutin, and one patient switched while
taking carbamazepine. Within the group of patients
that remained on TDF, treatment with rifampicin
(n = 12), rifabutin (n = 14) and carbamazepine (n = 3)
Table 1 Characteristics of the study population at baselinea
Characteristics No TDF-toxicity risk
N = 4′360
TDF-toxicity risk
N = 652
P
Male sex (%) 3194 (73.3) 451 (69.2) 0.03
Median age in years (IQR) 48 (40–54) 56 (50–62) < 0.001
African origin (%) 742 (17.0) 47 (7.2) < 0.001
High-level education (%) 1471 (33.7) 181 (27.8) 0.01
Transmission group (%) < 0.001
MSM 2071 (48.7) 270 (42.4)
PWID 396 (9.3) 108 (17.0)
other 1789 (42.0) 259 (40.7)
Median CD4 count in cells/μL (IQR) 640 (486–828) 615 (443–826) 0.01
Median CD4 nadir in cells/μL (IQR) 226 (122–334) 171 (75–273) < 0.001
Type of center (%) 0.44
Tertiary care center 2256 (51.7) 348 (53.4)
Other 2104 (48.3) 304 (46.6)
Chronic HBV infection (%) 291 (7.1) 47 (7.5) 0.71
Chronic HCV infection (%) 509 (11.9) 115 (18.0) < 0.001
History of CV disease (%) 293 (6.7) 95 (14.6) < 0.001
Diabetes (%) 245 (5.6) 77 (11.8) < 0.001
Arterial hypertension (%) 2264 (51.9) 405 (62.1) < 0.001
Dyslipidemia (%) 1′864 (42.8) 345 (52.9) < 0.001
Median eGFR in mL/min (IQR) 93.8 (80.6–106.3) 73.0 (56.3–95.5) < 0.001
eGFR category (%) < 0.001
> 90 mL/min 2390 (57.3) 198 (30.9)
60–90mL/min 1782 (42.7) 200 (31.2)
< 60 mL/min 0 243 (37.9)
Proteinuria (%) [n = 3102] < 0.001
< 15 mg/mmol 1920 (72.5) 139 (30.6)
15–50mg/mmol 727 (27.5) 162 (35.6)
> 50 mg/mmol 0 154 (33.9)
Osteoporosis (%) n.a.
T-score≤ −2.5 [n = 1624] 0 273 (41.9)
Fragility fracture 0 77 (11.8)
Combined 0 325 (49.9)
PI-based ART (%) 994 (22.8) 184 (28.2) 0.01
NNRTI-based single-pill regimen (%) 1755 (40.3) 223 (34.2) 0.01
TDF Tenofovir disoproxil fumarate, IQR Interquartile range, MSM Men having sex with men, PWID Persons who inject drugs, HBV Hepatitis B virus, HCV Hepatitis C
virus, CV Cardiovascular, eGFR Estimated glomerular filtration rate, PI Protease inhibitor, ART Antiretroviral treatment, NNRTI Non-nucleoside reverse
transcriptase inhibitor
atime of switch for those who switched, or 1st October 2016 (introduction of TAF in Switzerland) or registration date if registered after that date for those who did
not switch
TDF toxicity risk defined as presence of a least one of the following risk factors: eGFR < 60mL/min, urine protein-to-creatinine ratio of ≥50 mg/mmol
or osteoporosis
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were more common. No patient in the study popula-
tion received phenytoin.
Discussion
Two years after the introduction of TAF in Switzerland,
56% of all patients on TDF-containing ART overall, and
72% of those with risk factors for TDF-associated tox-
icity had TDF replaced by TAF. The highest proportions
of patients switched to TAF were found in men, those
older than 50 years, as well as in individuals with renal
impairment, whereas the use of a NNRTI-based single-
pill regimen was predictive of staying on TDF. The main
reason for switching to TAF, as reported by treating
physicians, was the prevention of potential side effects
due to TDF. Our study underlines the importance of
monitoring treatment changes and related predictors in
Table 2 Predictors of switching from TDF to TAF
Multivariable Analysis
Variable N (%) Switched (%) Adjusted odds ratio
(95% CI)
P
Male sex 3′645 (72.7) 2′102 (57.7) 1.27 (1.07–1.50) 0.01
Age > 50 years 2′235 (44.6) 1′413 (63.2) 1.43 (1.23–1.66) < 0.001
African origin 789 (15.7) 377 (47.8) 0.83 (0.67–1.01) 0.07
High level education 1′652 (33.0) 923 (55.9) 1.16 (1.00–1.35) 0.05
CD4 < 500/μL at baselinea 1′406 (28.1) 754 (53.6) 0.77 (0.66–0.90) < 0.001
Follow-up in a non-tertiary care center 2′408 (48.0) 1′169 (48.6) 0.56 (0.46–0.70) < 0.001
Comorbidities
Chronic HBV infection 338 (6.7) 188 (55.6) 0.97 (0.74–1.26) 0.81
Chronic HCV infection 624 (12.5) 349 (55.9) 0.66 (0.54–0.80) < 0.001
Diabetes 322 (6.4) 202 (62.7) 0.95 (0.71–1.26) 0.70
Arterial hypertension 2′669 (53.3) 1′584 (59.4) 1.21 (1.04–1.40) 0.01
History of CV disease 388 (7.7) 243 (62.6) 0.79 (0.61–1.03) 0.08
Dyslipidemia 2′209 (44.1) 1′336 (60.5) 1.09 (0.94–1.26) 0.26
At least one risk factor for TDF toxicityb 652 (13.0) 465 (71.3) 2.21 (1.77–2.75) < 0.001
PI-based ART 1′178 (23.5) 855 (72.6) 0.97 (0.81–1.16) 0.74
NNRTI-based single-pill regimen 1′978 (39.5) 522 (26.4) 0.11 (0.09–0.13) < 0.001
TDF Tenofovir disoproxil fumarate, TAF Tenofovir alafenamide, HBV Hepatitis B virus, HCV Hepatitis C virus, CV Cardiovascular, PI Protease inhibitor, ART
Antiretroviral treatment, NNRTI Non-nucleoside reverse transcriptase inhibitor
atime of switch for those who switched, or 1st October 2016 (introduction of TAF in Switzerland) or registration date if registered after that date for those who did
not switch
bosteoporosis, impaired renal function or marked proteinuria
Fig. 1 Rates of switching from TDF to TAF, according to risk factor. eGFR Estimated glomerular filtration rate, TDF Tenofovir disoproxil fumarate,
TAF Tenofovir alafenamide. Proteinuria defined as urine protein-to-creatinine ratio > 50 mg/mmol
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order to evaluate a program’s potential to react to
changes in guidelines and new drug availability, as well
as to foster patient-centered management.
Although the majority of individuals on TDF-
containing ART were switched to TAF, we found large
differences in the use of TAF across treatment sites and
between tertiary and non-tertiary sites. Similar diversity
in patterns of treatment changes were observed across
other studies: in a cohort of 444 patients on TDF-
containing ART in Germany, only 34% of all patients
switched to TAF-containing ART within 2 years of its
introduction [15]. In contrast, a retrospective analysis of
four treatment centers in the US showed that of all
switches performed within the first year after TAF be-
came available, 86% received TAF as the new drug [16].
The lower cost of F/TAF compared to F/TDF in coun-
tries without generic F/TDF could partly explain these
results: for instance, generic F/TDF was available in
Germany but not in the US and Switzerland. Further-
more, some physicians may have decided to wait for the
availability of generic F/TDF instead of switching indi-
viduals without risk factors for TDF-toxicity to TAF.
Eventually, these generic compounds never made it to
the market in Switzerland due to legal issues.
Our study highlights the multitude of factors which
potentially play a role in shaping physicians’ choices and
patient preferences in terms of ART modalities. Al-
though only 8.2% of all switches in our study could be
attributed to the presence of established kidney dysfunc-
tion, as reported by treating physicians, a low eGFR
Fig. 2 Probability of switching from TDF to TAF. Adjusted odds ratios (aOR) and 95% confidence intervals (CI) in study population without (Panel
a) and with risk factors for TDF-associated toxicity (Panel b). aOR Adjusted odds ratio, HBV Hepatitis B virus, HCV Hepatitis C virus, CV
Cardiovascular disease, eGFR Estimated glomerular filtration rate, PI Protease inhibitor, ART Antiretroviral treatment, NNRTI Non-nucleoside reverse
transcriptase inhibitor
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(especially below 60mL/min) was a predictor for receiv-
ing TAF. This finding is in line with previous reports
[16–18] and such a strategy is supported by the results
of randomized controlled trials in patients with renal
impairment [10, 19]. The presence of boosted PI-
based regimens was not associated with an increase
in switching to TAF in our study, even though these
patients are at increased risk of TDF-associated tox-
icity. In a randomized controlled trial, Goicoechea
et al. showed a faster decline in renal function when
TDF was co-administered with boosted PI, possibly
due to increased tenofovir plasma levels [20]. Simi-
larly, a meta-analysis of randomized trials only fa-
vored TAF over TDF for renal outcomes when a
booster was co-administered [21]. The single most
important predictor of staying on TDF was the use of
NNRTI-based single-pill regimens. For these regi-
mens, TAF-containing counterparts were either un-
available as a single-pill or introduced late during the
observation period. We hypothesize that even in the
presence of risk factors, patients and physicians may
have preferred to keep the convenient and well-
tolerated single-pill regimen in order to secure adher-
ence and virological efficacy. Many patients without
risk factors for TDF-toxicity remained on TDF in our
cohort, a practice supported by the EACS guidelines
[12] and current data which are insufficient to recom-
mend TAF over TDF for these patients. Since TDF is
available in generic form in many countries, its use
could considerably reduce HIV-related costs.
In general, the potential for DDI of TDF and TAF is
similar. However, drugs such as carbamazepine, pheny-
toin, rifampicin or rifabutin seem to be more problem-
atic when combined with TAF than with TDF [14]. For
instance, the administration of TAF in combination with
rifampicin led to significantly lower intracellular and
plasma levels of tenofovir in pharmacokinetic studies
[19, 22]. While twice-daily dosing of TAF is sufficient to
overcome the decrease in plasma levels induced by ri-
fampicin and rifabutin, carbamazepine or phenytoin
seem to decrease tenofovir plasma levels to an extent
that TAF can lose its therapeutic effect. Despite the
nearly systematic switch to TAF in some of our study
centers, only one of 2′796 patients who switched to TAF
was receiving a contra-indicated co-medication (carba-
mazepine). Considering the very low number of inad-
equate drug combinations after the switch to TAF, our
study shows that the event of significant DDI in the con-
text of single-drug substitutions remains very low when
HIV physicians are familiar with important DDI
mechanisms.
The large number of patients analyzed during the
months following the registration of TAF in Switzerland
allowed us to explore the main drivers of ART changes
in response to the availability of drugs with an improved
toxicity profile. Furthermore, the presence of detailed in-
formation on treatment changes and stopping reasons
helped us improve our understanding of the determi-
nants of switching from TDF- to TAF-containing ART.
However, although this study is representative for
current treatment strategies in Switzerland, extrapola-
tions to other health care systems should be undertaken
with caution. Additionally, given the large number of po-
tentially nephrotoxic drugs with complex toxicity pro-
files taken by our patients, we could not include
comprehensive information on their use in our analysis.
As the prescription of such drugs may have motivated
physicians to recommend switching to a TAF-containing
regimen, we may have failed to grasp the reason for
switching in some cases. Similarly, as the assessment of
bone mineral density was available in only 32% of our
study population, we may have underestimated the pro-
portion of patients at risk of TDF-toxicity. The potential
under-estimation of osteoporosis in our cohort was
Table 3 Reasons for switching from TDF to TAF
TDF stopping reason No TDF-toxicity risk
(n = 2′331)
TDF-toxicity risk
(n = 465)
Total
(n = 2′796)
Prevention of expected side-effects 614 (26.3%) 83 (17.9%) 697 (24.9%)
Established kidney toxicity 147 (6.3%) 83 (17.9%) 230 (8.2%)
Toxicity, other 124 (5.3%) 34 (7.3%) 158 (5.7%)
Treatment simplification 223 (9.6%) 34 (7.3%) 257 (9.2%)
Drug-drug interaction 15 (0.6%) 3 (0.7%) 18 (0.6%)
Patient’s wish 195 (8.4%) 48 (10.3%) 243 (8.7%)
Physician’s decision 375 (16.1%) 88 (18.9%) 463 (16.6%)
Other reason, not specified 581 (24.9%) 85 (18.3%) 666 (23.8%)
Missing 57 (2.5%) 7 (1.5%) 64 (2.3%)
TDF Tenofovir disoproxil fumarate, TAF Tenofovir alafenamide.
TDF toxicity risk defined as presence of a least one of the following risk factors: eGFR < 60mL/min, urine protein-to-creatinine ratio of ≥50 mg/mmol
or osteoporosis
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mitigated by our inclusion of data on fragility fractures
systematically collected within the SHCS. Since TAF is
not recommended during pregnancy, the desire to have
children may have influenced treatment choices in some
women and led to lower switching rates among this
group of patients. Finally, information about physicians’
motivation to recommend a treatment change to their
patients was limited to predefined stopping reasons and
were inconclusive in almost 50% of cases. Such informa-
tion would have been important to better understand
the large differences in TAF prescriptions between ter-
tiary centers and other health care facilities.
Conclusions
The majority of patients at risk for TDF-toxicity were
switched from TDF to TAF within two years after its
introduction in Switzerland. Among 30% of patients at
risk of TDF-toxicity who did not switch during this
time-period, being on a NNRTI-based single-pill regi-
men seemed to be an important reason for remaining on
TDF. However, large differences across clinics were ob-
served and related reasons should be further explored.
Since current recommendations on switching to TAF
are based on limited data from selected groups of pa-
tients in randomized controlled trials, further data on
clinical outcomes after the introduction of TAF in co-
horts such as ours remain essential to inform optimal
patient management.
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